337 related articles for article (PubMed ID: 23495824)
21. Quantitative assessment of small bowel motility in patients with Crohn's disease using dynamic MRI.
Hahnemann ML; Nensa F; Kinner S; Köhler J; Gerken G; Umutlu L; Lauenstein TC
Neurogastroenterol Motil; 2015 Jun; 27(6):841-8. PubMed ID: 25808321
[TBL] [Abstract][Full Text] [Related]
22. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
23. Correlation between faecal calprotectin and magnetic resonance imaging (MRI) in the evaluation of inflammatory pattern in Crohn's disease.
Zippi M; Al Ansari N; Siliquini F; Severi C; Kagarmanova A; Maffia C; Parlanti S; Garbarino V; Maccioni F
Clin Ter; 2010; 161(2):e53-6. PubMed ID: 20499020
[TBL] [Abstract][Full Text] [Related]
24. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn's disease.
Egea Valenzuela J; Pereñíguez López A; Pérez Fernández V; Alberca de Las Parras F; Carballo Álvarez F
Rev Esp Enferm Dig; 2016 Jul; 108(7):394-400. PubMed ID: 27312194
[TBL] [Abstract][Full Text] [Related]
25. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease.
Weinstein-Nakar I; Focht G; Church P; Walters TD; Abitbol G; Anupindi S; Berteloot L; Hulst JM; Ruemmele F; Lemberg DA; Leach ST; Cytter R; Greer ML; Griffiths AM; Turner D;
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1089-1097.e4. PubMed ID: 29501599
[TBL] [Abstract][Full Text] [Related]
26. MR imaging in Crohn's disease: correlation of MR motility measurement with histopathology in the terminal ileum.
Cullmann JL; Bickelhaupt S; Froehlich JM; Szucs-Farkas Z; Tutuian R; Patuto N; Dawson H; Patak MA
Neurogastroenterol Motil; 2013 Sep; 25(9):749-e577. PubMed ID: 23741963
[TBL] [Abstract][Full Text] [Related]
27. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
[TBL] [Abstract][Full Text] [Related]
28. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.
Cerrillo E; Beltrán B; Pous S; Echarri A; Gallego JC; Iborra M; Pamies J; Nos P
Inflamm Bowel Dis; 2015 Jul; 21(7):1572-9. PubMed ID: 26052967
[TBL] [Abstract][Full Text] [Related]
29. Faecal calprotectin in the assessment of Crohn's disease activity.
Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF
QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440
[TBL] [Abstract][Full Text] [Related]
30. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease.
Eder P; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
Pol Arch Med Wewn; 2008 Nov; 118(11):622-6. PubMed ID: 19140565
[TBL] [Abstract][Full Text] [Related]
31. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
32. Magnetic resonance enterography, colonoscopy, and fecal calprotectin correlate in colonic Crohn's disease.
Somwaru AS; Khanijow V; Katabathina VS
BMC Gastroenterol; 2019 Dec; 19(1):210. PubMed ID: 31805875
[TBL] [Abstract][Full Text] [Related]
33. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
[TBL] [Abstract][Full Text] [Related]
34. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin.
Makanyanga JC; Pendsé D; Dikaios N; Bloom S; McCartney S; Helbren E; Atkins E; Cuthbertson T; Punwani S; Forbes A; Halligan S; Taylor SA
Eur Radiol; 2014 Feb; 24(2):277-87. PubMed ID: 24026620
[TBL] [Abstract][Full Text] [Related]
36. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn's disease.
Daniluk U; Daniluk J; Krasnodebska M; Lotowska JM; Sobaniec-Lotowska ME; Lebensztejn DM
Adv Med Sci; 2019 Mar; 64(1):9-14. PubMed ID: 30237086
[TBL] [Abstract][Full Text] [Related]
37. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
[TBL] [Abstract][Full Text] [Related]
38. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
Zubin G; Peter L
Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
[TBL] [Abstract][Full Text] [Related]
39. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
